Trial Profile
A phase Ib trial investigating huperzine-A in (BIS-001) in patients with refractory epilepsy
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2016
Price :
$35
*
At a glance
- Drugs Huperzine A (Primary)
- Indications Complex partial epilepsy
- Focus Adverse reactions; Proof of concept
- 24 Oct 2016 According to Biscayne Pharmaceuticals media release, company expects to advance this study in mid-2017.
- 28 Jun 2016 According to Biscayne Pharmaceuticals media release, company plans to initiate this study later this year.
- 28 Jun 2016 Planned initiation date changed from 1 Jan 2016 to 1 Nov 2016, as per Biscayne Pharmaceuticals media release.